Impact of SOFT/TEXT in Premenopausal Breast Cancer

Video

This video reviews the impact of the SOFT/TEXT trials for the treatment of patients with premenopausal breast cancer, and ways to best use the results.

In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews the impact of the SOFT/TEXT trials for the treatment of premenopausal breast cancer patients, and ways to best use the results.

Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
Related Content
Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

Roman Fabbricatore
June 22nd 2025
Article

Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Radhika Appaya;Mario Campone;Louise Emmett;Dejan Juric;Debasish Tripathy;Sonia Pernas;Monica Zuradelli;Kevin Perraud;Aleix Prat
June 21st 2025
Article

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

Russ Conroy
June 20th 2025
Article

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

Radhika Appaya;Paolo Tarantino, MD;Hope S. Rugo, MD;Guiseppe Curigliano;Joyce O’Shaughnessy, MD;Wolfgang Janni;Komal Jhaveri;Jason Mouabbi;Adam M. Brufsky, MD, PhD;Erika P. Hamilton, MD;Ruth M. O’Regan; Julia Kim;Liz Santarsiero;Murat Akdere;Fen Ye;Henry Owusu;Stephanie L. Graff, MD
June 20th 2025
Article